title: Regulation of neuronal mRNA translation by CaM-kinase I phosphorylation of eIF4GII.
abstract: Ca²⁺/calmodulin-dependent kinases (CaMKs) are essential for neuronal development and plasticity, processes requiring de novo protein synthesis. Roles for CaMKs in modulating gene transcription are well established, but their involvement in mRNA translation is evolving. Here we report that activity-dependent translational initiation in cultured rat hippocampal neurons is enhanced by CaMKI-mediated phosphorylation of Ser1156 in eukaryotic initiation factor eIF4GII (4GII). Treatment with bicuculline or gabazine to enhance neuronal activity promotes recruitment of wild-type 4GII, but not the 4GII S1156A mutant or 4GI, to the heterotrimeric eIF4F (4F) complex that assembles at the 5' cap structure (m⁷GTP) of mRNA to initiate ribosomal scanning. Recruitment of 4GII to 4F is suppressed by pharmacological inhibition (STO-609) of CaM kinase kinase, the upstream activator of CaMKI. Post hoc in vitro CaMKI phosphorylation assays confirm that activity promotes phosphorylation of S1156 in transfected 4GII in neurons. Changes in cap-dependent and cap-independent translation were assessed using a bicistronic luciferase reporter transfected into neurons. Activity upregulates cap-dependent translation, and RNAi knockdown of CaMKIβ and γ isoforms, but not α or δ, led to its attenuation as did blockade of NMDA receptors. Furthermore, RNAi knockdown of 4GII attenuates cap-dependent translation and reduces density of dendritic filopodia and spine formation without effect on dendritic arborization. Together, our results provide a mechanistic link between Ca²⁺ influx due to neuronal activity and regulation of cap-dependent RNA translation via CaMKI activation and selective recruitment of phosphorylated 4GII to the 4F complex, which may function to regulate activity-dependent changes in spine density.
authors.affiliation: Vollum Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.
authors.forename: Taasin
authors.initials: T
authors.lastname: Srivastava
authors.forename: Dale A
authors.initials: DA
authors.lastname: Fortin
authors.forename: Sean
authors.initials: S
authors.lastname: Nygaard
authors.forename: Stefanie
authors.initials: S
authors.lastname: Kaech
authors.forename: Nahum
authors.initials: N
authors.lastname: Sonenberg
authors.forename: Arthur M
authors.initials: AM
authors.lastname: Edelman
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Soderling
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects / Q000235:genetics; D054729:Calcium-Calmodulin-Dependent Protein Kinase Type 1 / Q000235:genetics / Q000378:metabolism*; D002478:Cells, Cultured; D002614:Chelating Agents / Q000494:pharmacology; D003712:Dendrites / Q000235:genetics; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004622:Embryo, Mammalian; D039603:Eukaryotic Initiation Factor-4G / Q000235:genetics / Q000378:metabolism*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D055785:Gene Knockdown Techniques; D006624:Hippocampus / Q000166:cytology; D006801:Humans; D047468:Immunoprecipitation; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000235:genetics; D009154:Mutation / Q000235:genetics; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010759:Phosphorus Isotopes / Q000493:pharmacokinetics; D010766:Phosphorylation / Q000187:drug effects / Q000235:genetics; D011724:Pyridazines / Q000494:pharmacology; D012315:RNA Caps / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012694:Serine / Q000235:genetics; D026941:Sodium Channel Blockers / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D013779:Tetrodotoxin / Q000494:pharmacology; D014162:Transfection / Q000379:methods
chemical_list: D002614:Chelating Agents; C491300:EIF4G2 protein, human; D039603:Eukaryotic Initiation Factor-4G; D018691:Excitatory Amino Acid Antagonists; D058787:GABA-A Receptor Antagonists; D010759:Phosphorus Isotopes; D011724:Pyridazines; D012315:RNA Caps; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D026941:Sodium Channel Blockers; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D013779:Tetrodotoxin; D012694:Serine; D004533:Egtazic Acid; D000255:Adenosine Triphosphate; C049853:gabazine; C546845:mTOR protein, rat; D058570:TOR Serine-Threonine Kinases; D054729:Calcium-Calmodulin-Dependent Protein Kinase Type 1; D001640:Bicuculline